Le Lézard
Classified in: Health
Subject: ATY

Parker Waichman LLP Comments: DePuy Synthes Attune Knee Device Lawsuits Mounting



PORT WASHINGTON, N.Y., Oct. 5, 2017 /PRNewswire/ -- Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims injured by allegedly defective drugs and medical devices, is commenting on DePuy Synthes Attune Knee Replacement problems. Reports submitted to the U.S. Food and Drug Administration (FDA) reveal an increased number of Attune failures are due, allegedly, to loosening?or debonding?at the cement border of the tibial baseplate. Premature failure typically takes place one-two years following implant, if not earlier. Such debonding of the tibial baseplate or tray leads to pain, swelling, inflammation, infection, instability, severe bone and/or muscle loss and damage, and other injuries, all necessitating more medical procedures or surgeries to remove and replace the device (revision surgery). Revision surgery is generally more painful, difficult, and costlier than initial surgery, especially if bone loss has developed. Revision surgery also generally involves longer, more complex therapy ad recovery.

"Parker Waichman represents many patients implanted with the Attune knee implant system who have subsequently suffered from serious and painful complications," says Keith Gitman, Managing Attorney. Parker Waichman is a nationwide law firm representing victims of the Attune knee system and continues to offer free legal reviews to individuals who allegedly suffered complications related to the Attune system.

Symptoms of Attune Knee implant failure may include instability and loosening, unusual swelling, persistent pain, warmth or heat in the knee, loss of or failure to bond of the system to bond to the bone, worn components, fracture, loss of osseointegration (loss of direct structural and functional connection between ordered, living bone and the surface of a load-carrying implant), and metal shedding debris.

Also, according to Mr. Gitman, "Whistleblowers are crucial in detecting and stopping fraud and are critical to ending illegal employer activities that may cause harm to patients." Mr. Gitman adds that, "Whistleblowers have long been crucial in helping to stop illegal activities by various entities, including medical device makers. Parker Waichman has also been involved in resolving cases involving fraud and have been equally important in maintaining whistleblower anonymity in these cases."

"This case opens up the potential for other cases of fraud to emerge," said Mr. Gitman.  "When medical device companies take part in illegal or unethical activities such as releasing potentially defective devices to the market, they are defrauding unsuspecting patients and physicians," added Mr. Gitman.

Filing a DePuy Synthes Attune Knee Replacement System Lawsuit

Parker Waichman LLP supports efforts to protect whistleblowers and offers free case evaluations to those individuals who believe their companies may be involved in wrongdoings.  Parker Waichman has also long represented clients in medical device injury lawsuits. If you or someone you know is interested in filing a DePuy Synthes Attune Knee Replacement System lawsuit, or if you believe that a device maker is committing fraudulent activities and would like to maintain your anonymity, contact Parker Waichman LLP at the firm's website at www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).

SOURCE Parker Waichman LLP


These press releases may also interest you

at 21:00
Half of all individuals in Canada born with cystic fibrosis will not live past around 50 years of age. Emily Lyons ? successful serial entrepreneur and CEO of multiple Toronto-based companies ? experienced firsthand the reality of this sobering...

at 18:14
A new study released today by the Pacific Research Institute finds that a program to give discounted prescription drugs to poor Americans is riddled with abuse, has created a perverse incentive for providers to profit instead of effectively serve the...

at 17:33
Helix BioPharma Corp. , an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending October 31, 2017. FINANCIAL REVIEW...

at 17:03
DiaMedica Therapeutics Inc. (the "Company") , announces that, subject to TSX Venture Exchange approval, it is undertaking a non-brokered private placement for gross proceeds of approximately CAD$1 million (approximately USD$780,000) with the...

at 16:48
Avion pharmaceuticals, LLC, and their partner company, Acella Pharmaceuticals, recently responded to the recent news surrounding the Avondale Pharmaceuticals product Niacor, a prescription version of niacin.  Avion and Acella were made aware of the...

at 16:36
The Royal Canadian Mounted Police (RCMP) today announced the results of its unfounded sexual assault file review, and outlined actions the organization is taking to strengthen sexual assault investigations, oversight and victim support. Earlier...




News published on 5 october 2017 at 08:45 and distributed by: